MVA Good Morning Meeting – cGMP Natural & Synthetic Phospholipids for Complex Drug Delivery Systems and Vaccines
Learn about the benefits of phospholipids in pharmaceutical dosage forms and innovative drug delivery systems.
Natural and synthetic phospholipids are ideal multi-purpose excipients with an unrivalled safety profile in state-of-the-art pharmaceutical dosage forms. In innovative drug delivery systems phospholipids – as enabling excipients – are crucial for ensuring the efficacy of therapeutics and vaccines.
Within this presentation the focus will be on phospholipids for parenteral and pulmonary administration. Phospholipids can be found in different types of formulations, such as emulsions, liposomes, or solid lipid nanoparticles. Moreover, they can be administered to the lungs for local and systemic delivery of actives.
Join us in this seminar to learn more about the prominent role of phospholipids in pharmaceutical applications. In this seminar we will touch upon topics such as the benefits of phospholipids in:
• mRNA vaccines and adjuvant systems
• Pulmonary applications
• Depot formulations
Date: Tuesday 20th of September 2022
Time: 9:00 – 11:00 CET
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium
|09:00||Networking, registration, and light breakfast|
David Munis Zepernick, Head of Member Engagement and Communication, Medicon Valley Alliance
Peter Hölig, Head of Business Development, Lipoid
|09:40||cGMP Natural & Synthetic Phospholipids for Complex Drug Delivery Systems and Vaccines|
Peter van Hoogevest, Consultant, CEO and Owner at Pharmanovation
|11:00||End of Good Morning Meeting|
|Dr. Peter Hölig, Head of Business Development at Lipoid, is a licensed pharmacist. He received a PhD in Pharmaceutical Technology on targeted liposomes for cancer therapy. Prior joining Lipoid he held scientific, technical, and strategic roles of increasing responsibility in the pharmaceutical and chemical industry. He has authored several publications and patent applications. In addition, he is a member of the board of the Phospholipid Research Center.|
|Dr. Peter van Hoogevest, Consultant, CEO and Owner at Pharmanovation, is a pharmacist by training (Utrecht University in The Netherlands), who got his PhD degree in biochemistry 1984 at the Utrecht University in The Netherlands. In 1994 he received the degree of Privatdozent (adjunct professor) in pharmacy at the University of Basel, Switzerland.|
His industrial career started at the Biovet Group of the Animal Health Division of Ciba-Geigy Ltd. (Basel) in 1984. Shortly thereafter he obtained a position at the Novel Dosage Form Department of Pharmaceutical Development of the Pharmaceuticals Division of Ciba-Geigy Ltd. After having several positions at this department at Ciba Ltd. and Novartis Ltd. he founded in 1998 together with colleagues of the Pharmaceutical Development Department and reputed industrial managers and scientists the company ADD Advanced Drug Delivery Technologies (Muttenz, CH) and became CEO of this company and was member of the Board of Directors. In 2000 he joined Phares Drug Delivery AG (Muttenz, CH), a company specialized in the delivery of poorly water soluble drug substances, as Managing Director and COO and member of the Board of Directors. From 2012 till 2021 he was Managing Director of the Phospholipid Research Center, Heidelberg and Head of the Scientific Department (including the Development Department) of Lipoid GmbH, Ludwigshafen am Rhein, Germany). He runs from 2021 on his own consulting business PHARMANOVATION, based in Rheinfelden (Baden) , Germany.
His drug delivery expertise, especially in the (phospho)lipid research and development area, is underscored by 78 scientific publications, including 8 book chapters, 33 symposium posters, co-promotion of 48 PhD Theses, 13 patents and 45 patent applications.
Lipoid as the global market leader for pharmaceutical grade phospholipids supplies them at industrial scale and supports drug and vaccine product development projects from the R&D to the commercial level. Our natural and nature-identical synthetic phospholipids are derived from plants, such as soy and sunflower, or eggs.
|Organized by||In collaboration with |
| || |